Supplementary Figure FS1 from Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma

Dermawan, Josephine Kam Tai; Nafa, Khedoujia; Mohanty, Abhinita; Xu, Yingjuan; Rijo, Ivelise; Casanova, Jacklyn; Villafania, Liliana; Benhamida, Jamal; Kelly, Ciara M.; Tap, William D.; Boland, Patrick J.; Fabbri, Nicola; Healey, John H.; Ladanyi, Marc; Lu, Chao; Hameed, Meera

doi:10.1158/2767-9764.22546951.v1

- No file added yet -

Supplementary Figure FS1 from Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma

journal contribution

posted on 2023-04-04, 02:22 authored by Josephine Kam Tai Dermawan, Khedoujia Nafa, Abhinita Mohanty, Yingjuan Xu, Ivelise Rijo, Jacklyn Casanova, Liliana Villafania, Jamal Benhamida, Ciara M. Kelly, William D. Tap, Patrick J. Boland, Nicola Fabbri, John H. Healey, Marc Ladanyi, Chao Lu, Meera Hameed

Overall and progression-free survival in DDCS patients with or without TERT alterations

Funding

HHS | NIH | National Cancer Institute (NCI)

History

ARTICLE ABSTRACT

DDCS is a rare, high-grade chondrosarcoma with a dismal prognosis. About 50%–80% of DDCS harbor IDH1/IDH2 mutations. We uncover a significant alteration of IDH-associated methylation profile in DDCS, which we propose is key to the progression to dedifferentiation. In this context, the potential effect of the use of IDH inhibitors is unclear but important to address, as clinical trials of selective IDH1 inhibitors showed worse outcome in DDCS.